Add BrightSurf on Google Email

Doubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic

New prescriptions for stimulants among adults with ADHD more than doubled since the COVID-19 pandemic, with the largest increases among younger adults. The trend is driven by improved recognition and treatment of ADHD in adulthood, as well as increased access to care and virtual health services.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateMar 9, 2026

Low-dose lithium for mild cognitive impairment

Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.

SourceJAMA Network·JournalJAMA Neurology·DateMar 2, 2026

GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients

A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...

SourceHarvard T.H. Chan School of Public Health·JournalThe Lancet Diabetes & Endocrinology·TypeObservational study·DateFeb 25, 2026

UT Health San Antonio research shows Alzheimer’s prevention potential in pairing cannabis ingredient, anti-inflammatory drug

A new study led by Dr. Chu Chen suggests that combining THC with celecoxib may improve cognition and reduce Alzheimer's-related brain pathology in mice. The combination produced better outcomes than low-dose THC alone, including improved learning and memory performance and reduced markers of neuroinflammation.

SourceThe University of Texas at San Antonio Health Science Center·JournalAging and Disease·TypeExperimental study·DateJan 28, 2026

Japanese version of rPATD validated to assess attitudes toward medication reductions among patients and caregivers

The Japanese version of the rPATD questionnaire has been validated to assess attitudes towards medication reductions among older adults and their caregivers in Japan. The tool is reliable, valid, and easily understood, facilitating shared decision-making between healthcare providers and patients.

SourceUniversity of Tsukuba·JournalExploratory Research in Clinical and Social Pharmacy·DateJan 26, 2026

Use of potentially inappropriate medications during end-of-life cancer care: Patterns and factors associated with deprescribing

Researchers analyzed medical records of 1,269 elderly patients with advanced cancer to find that over 70% were prescribed potentially inappropriate medications (PIMs), which declined closer to death. PIM discontinuation was more common among female patients, those with polypharmacy, and palliative care unit admissions.

SourceUniversity of Tsukuba·JournalPalliative Care and Social Practice·DateJan 19, 2026

Alliance trial reveals gene variant may affect prostate cancer drug efficacy

A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...

SourceAlliance for Clinical Trials in Oncology·JournalClinical and Translational Science·TypeExperimental study·DateJan 14, 2026

Lifesaving breakthrough in bacterial behavior

Researchers have made a groundbreaking discovery about how bacteria swim upstream to cause infections, pointing to new designs for biomedical devices that can prevent contamination. The study found that wider channels with faster counterflows are more prone to invasion, but sharp corner designs can inhibit bacterial growth.

SourceUniversity of Pennsylvania·JournalNewton·TypeExperimental study·DateJan 12, 2026

Tuberculosis: Scientists develop novel drug candidate for combating resistant pathogens

Researchers at Martin Luther University Halle-Wittenberg have developed a promising new substance that inhibits the ability of tuberculosis bacteria to produce energy and causes them to die. The compound, PRP020, targets the pathogen's ATP synthase but attacks a different site than existing drugs like bedaquiline.

SourceMartin-Luther-Universität Halle-Wittenberg·JournalJournal of Medicinal Chemistry·TypeExperimental study·DateDec 8, 2025

Antipsychotic medication use by older adults

A growing trend of antipsychotic medication prescription increases in older U.S. adults, with long-term care pharmacies being a primary source. Non-psychiatrist prescribers contribute to the trend, highlighting concerns over medication accessibility and oversight.

SourceJAMA Network·JournalJAMA Psychiatry·DateDec 3, 2025

Breakthrough pediatric kidney therapy emerges from U. Iowa research

Researchers at the University of Iowa Health Care have developed a new class of medication, pegcetacoplan, which directly targets the root cause of C3 glomerulopathy, a rare and severe kidney disease. The treatment has shown significant results, with up to 67% of children achieving complete remission and stabilization of kidney function.

SourceUniversity of Iowa Health Care·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 3, 2025

Long-term antidepressant use surges in Australia, sparking warnings of overprescribing

A new study found that long-term antidepressant use has increased by nearly 20% among young people aged 10-24, raising concerns about potential overprescribing. The study also found no meaningful improvement in efforts to wean patients off antidepressants, highlighting the need for a stronger framework for safely tapering medications.

SourceUniversity of South Australia·JournalPharmacoepidemiology and Drug Safety·TypeData/statistical analysis·DateDec 2, 2025

Behind the 2025 “shroom boom” hides a bad trip

The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...

SourceCity St George’s, University of London·JournalFinance and Society·TypeData/statistical analysis·DateNov 20, 2025

Healing the heart after a heart attack

A new patch developed by Texas A&M University researcher Dr. Ke Huang may offer a way to help the heart heal after a heart attack by delivering interleukin-4 directly to damaged heart tissue. The patch uses a microneedle system to promote repair and improve heart function without affecting the rest of the body.

SourceTexas A&M University·JournalCell Biomaterials·DateNov 19, 2025

Muscle protein linked to exercise opens new way to treat Alzheimer’s

Researchers at Florida Atlantic University have discovered a potential new treatment for Alzheimer's disease by targeting muscle protein Cathepsin B. The study found that increasing Ctsb in muscle tissue may offer protection against the effects of AD and promote brain cell growth, restoring protein balance and rebalancing brain activity.

SourceFlorida Atlantic University·JournalAging Cell·TypeExperimental study·DateNov 18, 2025

New molecule reduces ethanol intake and drinking motivation in mice, with sex-dependent differences

A new compound MCH11, a monoacylglycerol lipase inhibitor, shows promising effects in reducing alcohol consumption and motivation to drink in mice. The molecule exhibits anxiolytic and antidepressant properties with sex-dependent efficacy, correcting genetic alterations associated with alcohol use disorder.

SourceUniversidad Miguel Hernandez de Elche·JournalBiomedicine & Pharmacotherapy·TypeExperimental study·DateNov 11, 2025

Weight loss drugs don’t increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides

Researchers from Intermountain Health have found that GLP-1 receptor agonists do not increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides. Patients taking these medications had a four times lower risk of developing pancreatitis compared to those not on the medication.

SourceIntermountain Healthcare·TypeObservational study·DateNov 9, 2025

Practice pattern of aerosol drug therapy in acute respiratory distress syndrome patients: An aero-in-ICU study

The study highlights the frequent use of aerosol therapy in critically ill patients with acute respiratory distress syndrome (ARDS), with bronchodilators being the most commonly prescribed drugs. However, the lack of sound scientific evidence and randomized controlled trials suggests that standardized protocols are needed to align clin...

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeObservational study·DateOct 29, 2025

Home treatment with IV antibiotics could relieve NHS pressure

A University of East Anglia study found that treating patients at home with IV antibiotics can save the NHS over £3,500 per patient and potentially free-up vital hospital beds. The treatment involves having antibiotics prepared at home and continuously delivered into the bloodstream by an elastomeric pump.

SourceUniversity of East Anglia·JournalJournal of Clinical Pharmacy and Therapeutics·TypeObservational study·DateOct 28, 2025